Essilor: Publication of the 2013 Interim Financial Report

Thu Aug 29, 2013 12:30am EDT

* Reuters is not responsible for the content in this press release.

Essilor: Publication of the 2013 Interim Financial Report

Regulatory News:

The Essilor International 2013 Interim Financial Report (Paris:EI) is being published today.

The report comprises the interim consolidated financial statements, the interim management report, the statement by the person responsible for the interim financial report and the Auditors’ review report on the interim consolidated financial statements.

It can be downloaded from the Company’s website, www.essilor.com, in the “Publications & Downloads” section, or by clicking on: http://www.essilor.com/en/Investors/Pages/PublicationsDownloads.aspx

About Essilor

The world’s leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its corporate mission is to enable everyone around the world to access lenses that meet his or her unique vision requirements. To support this mission, the Company allocates more than €150 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Essilor’s flagship brands are Varilux®, Crizal®, Definity®, Xperio®, OptifogTM and Foster Grant®. It also develops and markets equipment, instruments and services for eyecare professionals.

Essilor reported consolidated revenue of approximately €5 billion in 2012 and employs around 50,700 people. It operates in some 100 countries with 22 plants, more than 400 prescription laboratories and edging facilities, as well as several research and development centers around the world.

For more information, please visit www.essilor.com.

The Essilor share trades on the NYSE Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices.

Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

Investor Relations and Financial Communications
Phone: +33 (0)1 49 77 42 16

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.